Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7821959 | 0.94 | AGTR1 (0.66) | AGTR1PPARG | |
| SCHEMBL7821306 | 0.94 | AGTR1 (0.59) | AGTR1 | |
| SCHEMBL7811003 | 0.93 | AGTR1 (0.60) | AGTR1 | |
| SCHEMBL7818942 | 0.93 | AGTR1 (0.60) | AGTR1 | |
| SCHEMBL7810802 | 0.93 | AGTR1 (0.60) | AGTR1 | |
| SCHEMBL6978910 | 0.92 | AGTR1 (0.68) | AGTR1 | |
| SCHEMBL7812897 | 0.92 | AGTR1 (0.53) | AGTR1 | |
| SCHEMBL7811655 | 0.92 | AGTR1 (0.52) | AGTR1 | |
| SCHEMBL7821038 | 0.91 | PPARG (0.53) | AGTR1PPARG | |
| SCHEMBL7823816 | 0.89 | PPARG (0.51) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0781276-B1 | PYRIMIDINONE DERIVATIVES | BORYUNG PHARM (KR) | 2001-12-12 | — | — | EP | claimed |
| EP-0781276-A1 | PYRIMIDINONE DERIVATIVES | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 1997-07-02 | — | — | EP | claimed |
| WO-1996008476-A1 | PYRIMIDINONE DERIVATIVES | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 1996-03-21 | — | — | WO | claimed |
| EP-0781276-B1 | PYRIMIDINONE DERIVATIVES | BORYUNG PHARM (KR) | 2001-12-12 | — | — | EP | disclosed |
| EP-0781276-A1 | PYRIMIDINONE DERIVATIVES | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008476-A1 | PYRIMIDINONE DERIVATIVES | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 1996-03-21 | — | — | WO | disclosed |